The same evidence package, refused and then accepted, in uniQure’s own releases
In March the FDA would not accept this evidence package.
On 2 September, uniQure filed it.
uniQure filed a Biologics License Application with the FDA on 2 September 2026 for AMT-130 in Huntington’s disease, plus a UK marketing application. Both rest on a three-year Phase I/II analysis measured against an external control. Six months earlier, the FDA said that same comparison was not sufficient primary evidence.
What uniQure filed on 2 September
On 2 September 2026, uniQure announced the submission of a Biologics License Application to the FDA for the accelerated approval of ifezuntirgene inilparvovec (AMT-130). The same announcement said a Marketing Authorisation Application had gone to the UK’s Medicines and Healthcare products Regulatory Agency. Priority review has been requested for the BLA.
uniQure states that priority review, if granted, would shorten the FDA review cycle to six months. That cycle follows the agency’s 60-day BLA filing review period. Two clocks, then, not one.
The evidence line in that announcement is the one that matters. Both applications are supported by the previously announced three-year analysis from the Phase I/II study, against a propensity score-matched external control from Enroll-HD. That is an evidence package this same agency had declined six months earlier.
The analysis itself is not new. uniQure reported it on 24 September 2025.
High-dose patients showed a statistically significant 75% slowing of disease progression on the composite Unified Huntington’s Disease Rating Scale (cUHDRS) at 36 months, p=0.003. Twelve patients per dose group were evaluated at that time point, out of 29 treated.
The September announcement points back to that analysis rather than reporting new figures.
The position the FDA took in March
The external-control design was not a late improvisation. In June 2025, uniQure reported that the FDA had agreed on the primary efficacy analysis for the BLA. It compared the three-year cUHDRS change in high-dose patients to a propensity score-adjusted external control from Enroll-HD.
A BLA was planned for the first quarter of 2026.
It did not go in then. On 2 March 2026, uniQure reported the final minutes of a Type A meeting held on 30 January. The FDA stated it cannot agree that Phase I/II data, compared to an external control, are sufficient primary evidence of effectiveness.
The same minutes went further. The FDA strongly recommended that uniQure conduct a prospective, randomised, double-blind, sham surgery-controlled study. That is not a request for more of the same evidence, but for a different study.
The distinction has a physical cost here. AMT-130 is given once, through MRI-guided, convection-enhanced stereotactic neurosurgical delivery into the striatum. A sham-controlled registrational study means a control group that undergoes an imitation neurosurgical procedure, then years of follow-up.
What changed on 17 June
On 17 June 2026, uniQure announced the outcome of a recent Type B meeting with the FDA. The agency communicated that the three-year Phase I/II analysis would be acceptable as the primary basis of a BLA for accelerated approval. That is the same analysis, in the same role, that the March minutes had declined.
The confirmatory study moved too. The FDA sought to align on its design before the BLA submission, including consideration of a concurrent standard-of-care control instead of a sham procedure. uniQure said it was committed to conducting that study without delay.
The June release restated the design the agency had agreed to. Data from cohorts 1 and 2 compared to a propensity score-matched external control from Enroll-HD, under a prespecified statistical analysis plan. The sham arm went from the centre of a demanded new study to something the agency was considering replacing.
107 days separated uniQure’s report of a strong recommendation for a sham surgery-controlled study from its report of that same analysis being acceptable as the primary basis of a BLA.
Neither release reports a new clinical dataset arriving between them. The March release describes the Phase I/II data compared to an external control; the June release identifies that evidence as the three-year analysis against Enroll-HD. On these releases alone, what moved between March and June was the regulator’s position, not the dataset.
What the record does not show
Why the FDA moved is not stated anywhere in these sources. uniQure said it expected final minutes within 30 days of the Type B meeting; the releases do not publish them. What the agency weighed is not on this record.
Nor is the confirmatory study settled here. In June, uniQure said it expected to align with the FDA on that study’s details before the BLA submission. The submission has now been announced, and the announcement does not say whether that alignment was reached.
The 2 September release carries no safety data, no effect sizes and no p-values. It points back to the three-year analysis for all of it. Anyone modelling this filing is modelling a dataset with a 30 June 2025 cutoff.
The safety characterisation available here is from that earlier release, which described AMT-130 as generally well-tolerated with a manageable safety profile at both doses. As of the 30 June 2025 cutoff, no new drug-related serious adverse events had been observed since December 2022. Nothing in the September announcement updates that.
What this means for drug developers
uniQure’s designation claim is narrower than it looks. uniQure states it is the first investigational therapy for Huntington’s disease to have received Breakthrough Therapy and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA. The company says it also holds Fast Track.
It is not a claim to a first Huntington’s gene therapy BLA.
The question this submission answers is not whether AMT-130 works. It is what a regulator will accept as the primary basis of a registrational package when the disease moves slowly and the population is small. In March and in June, the same agency gave two different answers.
The two answers price differently. A prospective, sham-controlled study means recruiting and retaining patients through an imitation neurosurgical procedure for years. An external-control package means buying, curating and defending a natural history dataset instead.
If you've solved a problem like this, Drug Development and regulatory experts get matched to paid consulting work through GTC's Expert Network. Join free.
Those are not two variants of one plan. They differ in timeline, in budget shape, and in which vendor a program cannot afford to pick badly.
What this means for investors
Two clocks now govern the near-term news flow, and neither is uniQure’s to set. The 60-day filing review period runs first; priority review, if granted, then sets a six-month cycle after it. Neither outcome was known when the submission was announced.
The nearer catalyst is the company’s own. uniQure said it intends to present a four-year data analysis from the ongoing Phase I/II studies before the end of the current third quarter.
A fourth year deepens the durability question rather than widening the trial. uniQure has not said how many patients will have reached 48 months. The denominator behind that analysis is not yet public.
One thing the March-to-June sequence does establish is that a stated FDA position on this file has already moved once. A model that treats the current alignment as settled is treating as fixed something the record shows was not.
The wider impact on the field
Approximately 75,000 people have Huntington’s disease in the US, EU and UK, with no approved therapy to delay onset or slow progression. That combination of few patients and slow disease is exactly the setting where external controls get proposed.
Roughly 75,000 people in the US, EU and UK have Huntington’s disease. None of them has an approved therapy that slows it.
So the FDA’s handling of this file reads as a signal well beyond one company. What moved here was a position on what a registrational package may be built from. Every rare-CNS developer choosing between a concurrent control and an external one faces the same question.
What this means for a CGT program
Sourced fact: on 2 March 2026 the FDA could not agree that Phase I/II data compared to an external control were sufficient primary evidence. It strongly recommended a sham surgery-controlled study. On 17 June 2026 the FDA communicated that the same analysis would be acceptable as the primary basis of a BLA.
uniQure filed the BLA on 2 September 2026.
GTC analysis: regulatory decision. On this file, a stated agency position on external-control evidence in slow neurodegeneration moved inside a single year. The decision this changes is whether a refusal ends a pathway or schedules the next meeting.
A program that retired an external-control pathway on a first refusal retired it on a position that later reversed. One treating a current acceptance as durable is buying the same risk from the other side.
GTC analysis: timeline and budget decision. The distance between the two positions is, in study terms, roughly a Phase III of work. uniQure’s own route is the comparison point: two press releases 107 days apart, against the sham-controlled study the March minutes implied.
A contingency budget sized only for the study a program hopes to avoid is not sized for the engagement that avoids it.
GTC analysis: vendor decision. If external-control evidence can carry a registrational package, access to a credible natural history dataset stops being a statistics question and becomes a procurement one. Enroll-HD exists for Huntington’s.
Whether an equivalent exists for a given rare CNS indication is a question to answer years before the pivotal analysis, not during it.
That is as far as these sources go. They do not say why the FDA moved, and they do not publish the confirmatory study design. Nor do they report what the agency will decide on this BLA.
Frequently asked questions
What did uniQure submit on 2 September 2026, and to which regulators?
uniQure announced the submission of a Biologics License Application to the U.S. Food and Drug Administration. It seeks accelerated approval of ifezuntirgene inilparvovec (AMT-130), an investigational gene therapy for Huntington's disease. The company also announced a Marketing Authorisation Application submitted to the United Kingdom's Medicines and Healthcare products Regulatory Agency.
uniQure has requested priority review for the BLA. Both applications are supported by the previously announced three-year analysis from the Phase I/II study.
That analysis compared treated patients to a propensity score-matched external control derived from the Enroll-HD natural history database.
What did the FDA say about that evidence package in March 2026?
On 2 March 2026, uniQure announced it had received final meeting minutes from the FDA. They concerned a Type A meeting held on 30 January 2026. In those minutes the FDA stated it cannot agree that data from the Phase I/II studies, compared to an external control, are sufficient.
The standard the agency named was the primary evidence of effectiveness required to support a marketing application. The FDA strongly recommended that uniQure conduct a prospective, randomised, double-blind, sham surgery-controlled study.
uniQure said it intended to continue engaging with the FDA. It also planned to request a Type B meeting in the second quarter of 2026.
What changed on 17 June 2026?
uniQure announced that during a recent Type B meeting the FDA had communicated a change in position. The three-year analysis from the Phase I/II study would be acceptable as the primary basis of a BLA for accelerated approval of AMT-130. The FDA also sought to align on the confirmatory study design before the BLA submission.
That included consideration of a concurrent control on standard-of-care therapy instead of a sham procedure. uniQure said it was committed to conducting the confirmatory study without delay. It intended to submit the BLA in the third quarter of 2026.
The June release restated that data from cohorts 1 and 2 could be compared to a propensity score-matched external control derived from Enroll-HD. That comparison sits under a prespecified statistical analysis plan.
Did new clinical data arrive between the March and June positions?
None of these releases reports a new clinical dataset between the two. The 2 March 2026 release describes the Phase I/II data compared to an external control, without naming the timepoint or the dataset. The 17 June 2026 release identifies that evidence as the three-year analysis measured against an Enroll-HD external control.
That analysis was announced on 24 September 2025. It reported a statistically significant 75% slowing of disease progression in high-dose patients on the composite Unified Huntington's Disease Rating Scale at 36 months, p=0.003.
Twelve patients per dose group were evaluated at that time point, out of 29 treated. uniQure has said it intends to present a four-year analysis before the end of the third quarter of 2026.
The 2 September 2026 announcement describes the submissions as supported by the three-year analysis. None of these releases states why the FDA's position changed.
What happens next, and when?
uniQure has requested priority review. The company states that if priority review is granted, it would shorten the FDA review cycle to six months. That six-month cycle follows the FDA's 60-day BLA filing review period.
uniQure said it intends to present a four-year data analysis from the ongoing Phase I/II studies before the end of the current third quarter. uniQure states that ifezuntirgene inilparvovec is the first investigational therapy for Huntington's disease to have received Breakthrough Therapy and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA. The company says it also holds Fast Track designation.
Sources
- uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington's Disease – uniQure investor newsroom, 2 September 2026. Source for the BLA and MAA submissions, the accelerated approval and priority review requests, the review-timing statement, the evidence package supporting both applications, the delivery route, the designation wording, the four-year analysis timing, and the Huntington's disease prevalence figure.
- uniQure Announces Plan for BLA Submission for AMT-130 in Huntington's Disease – uniQure investor newsroom, 17 June 2026. Source for the FDA's Type B meeting communication that the three-year analysis would be acceptable as the primary basis of a BLA, the cohorts 1 and 2 external-control design under a prespecified statistical analysis plan, the standard-of-care rather than sham confirmatory control, the commitment to conduct that study without delay, and the 30-day final-minutes expectation.
- uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease – uniQure investor newsroom, 2 March 2026. Source for the final minutes of the 30 January 2026 Type A meeting: the FDA's statement that it cannot agree the Phase I/II data compared to an external control are sufficient primary evidence, and its strong recommendation of a prospective, randomised, double-blind, sham surgery-controlled study.
- uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington's Disease – uniQure investor newsroom, 24 September 2025. Source for every efficacy figure in this article, the patient numbers and follow-up counts, the propensity score-matched Enroll-HD external control, and the safety characterisation with its 30 June 2025 data cutoff.
- uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease – uniQure investor newsroom, 2 June 2025. A separate, earlier release. Source for the FDA's original agreement that the primary efficacy analysis would compare the three-year cUHDRS change against a propensity score-adjusted external control drawn from Enroll-HD, and for the first-quarter-2026 BLA plan.
Join the GTC Expert Network
Independent Experts
Independent experts in cell & gene therapy: share knowledge, help build a report, or contribute quietly. Build authority and get called for paid consulting work. Join free.
Early R&D Experts
Early R&D ExpertsContribute target validation, vector engineering, or transgene design expertise. Get matched to paid consulting work through content you help create.
Join FreeCMC Experts
CMC ExpertsContribute scale-up, tech transfer, or GMP manufacturing expertise. Get matched to paid consulting work through content you help create.
Join FreeRegulatory Affairs Experts
Regulatory Affairs ExpertsContribute IND/BLA strategy or regulatory liaison expertise. Get matched to paid consulting work through content you help create.
Join FreeCommercial & Strategy Experts
Commercial & Strategy ExpertsContribute due diligence, licensing, or market access expertise. Get matched to paid consulting work through content you help create.
Join FreeEnabling Technology Experts
Enabling Technology ExpertsContribute bioprocessing hardware, analytical tooling, or supply-chain expertise. Get matched to paid consulting work through content you help create.
Join FreeAI Transformation Experts
AI Transformation ExpertsContribute agentic workflow, LLM, or AI-driven vector design expertise. Get matched to paid consulting work through content you help create.
Join FreeIndustry Representatives
Industry professionals in cell & gene therapy: de-risk your pipeline with expert input on demand, exactly when your program needs it. Join free.
Drug Developers
Drug DevelopersFounders, CSOs, VPs of R&D
Practical guides spanning vector design through commercialization, plus direct access to the expert network that wrote them.
Join FreeInvestors / VCs
Investors / VCsVC Fund Managers, Family Offices, Angels
Due diligence frameworks and strategic intelligence for evaluating CGT assets, from experts who do this diligence for a living.
Join FreeTechnology Developers
Technology DevelopersFounders, Licensing & Commercial Leads
IP protection and platform strategy guides for enabling technologies, plus the network that built them.
Join FreeCDMOs / CROs
CDMOs / CROsBD, Operations & Technical Leads
Partner selection, vendor evaluation, and operational excellence guides, sourced from the CGT organisations that use them.
Join FreeVendors / Suppliers
Vendors / SuppliersCommercial & Technical Leads
Market intelligence and partnership strategies for supply chain companies serving cell and gene therapy.
Join FreeStrategy Consultants
Strategy ConsultantsConsultants, Market Access Advisors
Spot the problems before they cost your clients — join the network that shapes what GTC covers next.
Join FreeAI Transformation Partners
AI Transformation PartnersAI/ML Consultancies, Digital Transformation Firms
AI education, implementation, and consulting for operational excellence in cell and gene therapy — for companies building or buying AI capability.
Join FreeWhere the analysis comes from. Industry teams get expert input on demand; independent experts build authority and get called for paid consulting work.
See more of our work in Google Search
Google lets you pick the sites you want to see more often in Top Stories. Add Gene Therapy Consultancy to your list, and our daily gene therapy news will show up higher for you.